company background image
4539 logo

Nippon Chemiphar TSE:4539 Stock Report

Last Price


Market Cap







14 Jun, 2024


Company Financials

Nippon Chemiphar Co., Ltd.

TSE:4539 Stock Report

Market Cap: JP¥5.7b

4539 Stock Overview

Engages in the manufacture, sale, import, and export of ethical pharmaceuticals and diagnostic agents in Japan and internationally.

4539 fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health2/6

Nippon Chemiphar Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nippon Chemiphar
Historical stock prices
Current Share PriceJP¥1,580.00
52 Week HighJP¥2,112.00
52 Week LowJP¥1,550.00
1 Month Change-0.38%
3 Month Change-3.07%
1 Year Change-13.38%
3 Year Change-34.00%
5 Year Change-45.39%
Change since IPO-84.20%

Recent News & Updates

Recent updates

Shareholder Returns

4539JP PharmaceuticalsJP Market

Return vs Industry: 4539 underperformed the JP Pharmaceuticals industry which returned 0.2% over the past year.

Return vs Market: 4539 underperformed the JP Market which returned 16.6% over the past year.

Price Volatility

Is 4539's price volatile compared to industry and market?
4539 volatility
4539 Average Weekly Movement1.9%
Pharmaceuticals Industry Average Movement3.8%
Market Average Movement4.0%
10% most volatile stocks in JP Market7.5%
10% least volatile stocks in JP Market2.1%

Stable Share Price: 4539 has not had significant price volatility in the past 3 months.

Volatility Over Time: 4539's weekly volatility (2%) has been stable over the past year.

About the Company


Nippon Chemiphar Co., Ltd., together with its subsidiaries, engages in the manufacture, sale, import, and export of ethical pharmaceuticals and diagnostic agents in Japan and internationally. the company offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. It also develops NC-2400, a PPAR-delta agonist currently under phase 1 development; NC-2500, a XOR inhibitor for the treatment of hyperuricemia/gout currently under phase 1 development; and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain currently under phase 1 development.

Nippon Chemiphar Co., Ltd. Fundamentals Summary

How do Nippon Chemiphar's earnings and revenue compare to its market cap?
4539 fundamental statistics
Market capJP¥5.70b
Earnings (TTM)-JP¥180.00m
Revenue (TTM)JP¥30.75b


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4539 income statement (TTM)
Cost of RevenueJP¥23.01b
Gross ProfitJP¥7.74b
Other ExpensesJP¥7.92b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date


Earnings per share (EPS)-49.88
Gross Margin25.17%
Net Profit Margin-0.59%
Debt/Equity Ratio90.5%

How did 4539 perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.